Compare SPDR Gold Trust (GLD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Repligen Corporation Common Stock — how do they compare? SPDR Gold Trust trades at $380.72 (market cap $141.50B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: SPDR Gold Trust is far larger — about 12.5× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 75 Days and Repligen Corporation Common Stock for 0 Days on average.
| GLD | RGEN | |
|---|---|---|
Market Cap | $141.50B | $11.31B |
Volume | 5,707,251 | 1,216,919 |
52-Week High | $495.90 | $194.57 |
52-Week Low | $362.32 | $102.87 |
Typical Hold Time | 75 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, trades at $381.67, down 0.13% amid pressure from rising Treasury yields and a stronger U.S. dollar. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights gold's struggle to maintain momentum despite safe-haven demand, with prices testing key support levels near $380.
The outlook for GLD hinges on interest rate trends and macroeconomic uncertainty. While gold serves as a hedge against inflation and debt concerns, near-term headwinds from elevated yields and Fed policy uncertainty pose risks. A tactical buying opportunity may emerge if support holds, but sustained gains require a shift in monetary policy sentiment.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
